Rigel Pharmaceuticals (NASDAQ:RIGL) will issue its quarterly earnings data after the market closes on Monday, April 30th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). During the same period in the prior year, the company posted ($0.16) EPS. On average, analysts expect Rigel Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of RIGL opened at $3.84 on Monday. Rigel Pharmaceuticals has a fifty-two week low of $2.14 and a fifty-two week high of $4.71. The firm has a market capitalization of $565.90, a P/E ratio of -6.19 and a beta of 1.32.
A number of research analysts have weighed in on the stock. HC Wainwright set a $8.00 price objective on shares of Rigel Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, April 18th. Cantor Fitzgerald set a $6.00 price objective on shares of Rigel Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, April 17th. Jefferies Group boosted their price objective on shares of Rigel Pharmaceuticals to $7.00 and gave the company a “buy” rating in a research report on Wednesday, April 18th. They noted that the move was a valuation call. Piper Jaffray boosted their price objective on shares of Rigel Pharmaceuticals from $6.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, April 17th. Finally, BidaskClub cut shares of Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Rigel Pharmaceuticals has a consensus rating of “Buy” and an average target price of $6.71.
Rigel Pharmaceuticals Company Profile
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy.
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.